Ureter cancer is uncommon cancer that occurs in the cells present inside of the ureter tubes that connect kidneys to the bladder. It occurs in most of the older adults and closely related to bladder cancer. Blood in urine, back pain, pain when urinating, losing weight, and fatigue are some of the common symptoms of ureter cancer. Surgery, chemotherapy, and radiation are the treatments commonly employed to treat ureter cancer.
Rising cases of bladder cancer around the globe is a prime factor fueling the market growth of ureter cancer drugs. According to the Our World, in 2017, there were almost 85,239 death cases in 2017. Moreover, increasing launch of the advanced drug for the treatment of ureter cancer is further expected to propel the market growth. In May 2016, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to TECENTRIQ™ (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC).
North America is expected to gain significant growth over the forecast period and this can be attributed to the high prevalence of urological cancer in the region. According to the American Society of Clinical Oncology (ASCO), an estimated 80,470 adults (61,700 men and 18,770 women) in the United States are diagnosed with bladder cancer and the estimated death is 17,670 in 2019. Moreover, according to the U.S. Department of Health and Human Services, there were an estimated 699,450 people living with bladder cancer in the United States in 2016.
Furthermore, increasing launch of advanced drug for ureter cancer is also expected to foster the regional market growth. In April 2019, The U.S. Food and Drug Administration granted approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2.
Key Developments
• In November 2017, U.S. Food and Drug Administration (FDA) Approves Clinical Trial of drug-coated balloon catheter - the Optilume™, developed by Urotronic, based in Plymouth, MN, represents the first substantial investment in urology in a Medtech field.
• In May 2018, Ferring signs global agreement to commercialize novel gene therapy for bladder cancer patients who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.
• In May 2016, FDA approves a new immunotherapy drug, atezolizumab, which has been approved for patients with metastatic urothelial carcinoma, a type of bladder cancer. The drug is specifically approved for urothelial carcinoma arising in the urinary tract.
With the slowdown in world economic growth, the Ureter Cancer Drugs industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Ureter Cancer Drugs market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, Stratagem Market Insights analysts believe that in the next few years, Ureter Cancer Drugs market size will be further expanded, we expect that by 2025, The market size of the Ureter Cancer Drugs will reach XXX million $.
This Report covers the manufacturers' data, including shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume, and value, as well as price data.
Besides, the report also covers segment data, including type segment, industry segment, channel segment, etc. cover different segment market size, both volume, and value. It also covers different industry's clients information, which is very important for the manufacturers.
Section 1: Definition
Section (2 3): Manufacturer Detail
Altor BioScience Corp
Eisai Co Ltd
Exelixis Inc
GlaxoSmithKline Plc
MedImmune LLC
Merck & Co Inc
Section 4: Region Segmentation
North America Country (United States, Canada)
South America
Asia Country (China, Japan, India, Korea)
Europe Country (Germany, UK, France, Italy)
Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation
--Durvalumab
--Eribulin Mesylate
--Pembrolizumab
Industry Segmentation
--In-Patient
--Out-Patient
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2025)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
